Trial Profile
Treat and Extend Regimen with Aflibercept for Pachychoroid Neovasculopathy and Type 1 Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- 10 May 2018 New trial record